BACKGROUND AND PURPOSE:Abciximab has been shown to significantly reduce thromboembolic complications of coronary artery stenting. A prospective, randomized study was performed to test whether abciximab has comparable beneficial effects in carotid artery stenting. METHODS:Seventy-four consecutive patients undergoing elective stenting of the carotid artery were included in the study. Standard antithrombotic medication consisted of aspirin, clopidogrel, and heparin. In addition, half of the patients received an abciximab bolus of 0.25 mg/kg body weight given prophylactically before the intervention. RESULTS: The procedure was successful in all but 1 patient. In patients receiving abciximab, ischemic complications consisted of 4 transient ischemic attacks, 1 minor stroke, 1 nonfatal major stroke, and 1 fatal stroke caused by cerebral hemorrhage. In the control group, 2 transient ischemic attacks and 1 major nonfatal stroke occurred. In summary, the total number of periprocedural ischemic events was 7 (19%) in the abciximab group and 3 (8%) in the control group. Nonischemic complications consisted of 1 inguinal hematoma requiring blood transfusions in each group. CONCLUSIONS:Abciximab bolus given prophylactically before elective carotid artery stenting does not reduce ischemic complications.
RCT Entities:
BACKGROUND AND PURPOSE:Abciximab has been shown to significantly reduce thromboembolic complications of coronary artery stenting. A prospective, randomized study was performed to test whether abciximab has comparable beneficial effects in carotid artery stenting. METHODS: Seventy-four consecutive patients undergoing elective stenting of the carotid artery were included in the study. Standard antithrombotic medication consisted of aspirin, clopidogrel, and heparin. In addition, half of the patients received an abciximab bolus of 0.25 mg/kg body weight given prophylactically before the intervention. RESULTS: The procedure was successful in all but 1 patient. In patients receiving abciximab, ischemic complications consisted of 4 transient ischemic attacks, 1 minor stroke, 1 nonfatal major stroke, and 1 fatal stroke caused by cerebral hemorrhage. In the control group, 2 transient ischemic attacks and 1 major nonfatal stroke occurred. In summary, the total number of periprocedural ischemic events was 7 (19%) in the abciximab group and 3 (8%) in the control group. Nonischemic complications consisted of 1 inguinal hematoma requiring blood transfusions in each group. CONCLUSIONS:Abciximab bolus given prophylactically before elective carotid artery stenting does not reduce ischemic complications.
Authors: Jawad F Kirmani; Nazli Janjua; Ammar Al Kawi; Shafiuddin Ahmed; Ismail Khatri; Ali Ebrahimi; Afshin A Divani; Adnan I Qureshi Journal: NeuroRx Date: 2005-04
Authors: R Zahn; T Ischinger; M Hochadel; B Mark; U Zeymer; J Jung; A Schramm; K E Hauptmann; H Seggewiss; I Janicke; H Mudra; J Senges Journal: Clin Res Cardiol Date: 2007-06-27 Impact factor: 5.460